(Q36349687)

13 August 2017

1 reference

title

Tailoring antibodies for radionuclide delivery (English)

1 reference

13 August 2017

1 reference

Vania Kenanova

1

1 reference

13 August 2017

Anna M Wu

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Drug Delivery

13 August 2017

published in

1 reference

13 August 2017

volume

3

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

53-70

1 reference

Arming antibodies: prospects and challenges for immunoconjugates

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Antibody-targeted radiation cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Auger electron emitters: insights gained from in vitro experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Experimental radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Choosing an optimal radioimmunotherapy dose for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Antibodies from phage antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Antibody affinity maturation using bacterial surface display.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Yeast display of antibody fragments: a discovery and characterization platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

In-vitro protein evolution by ribosome display and mRNA display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Stability engineering of antibody single-chain Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Phage libraries for generation of clinically useful antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Tetravalent miniantibodies with high avidity assembling in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

New protein engineering approaches to multivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

A heterodimeric coiled-coil peptide pair selected in vivo from a designed library-versus-library ensemble.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Pretargeting strategies for radio-immunoguided tumour localisation and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Numerical selection of optimal tumor imaging agents with application to engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.53

21 January 2018

Identifiers

DOI

10.1517/17425247.3.1.53

1 reference

13 August 2017

1 reference